Navigation Links
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
Date:8/20/2008

vercoming nonsense mutations as the basis for treating genetic disease," said Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "Based on these results, we intend to initiate a Phase 2b study later this year to evaluate the clinical benefit of PTC124 in adults and children with nonsense-mutation-mediated CF. Given the potential applicability of PTC124 to multiple genetic disorders, we have a pivotal study of PTC124 for nonsense-mutation Duchenne/Becker muscular dystrophy ongoing and are planning proof-of-concept studies in additional genetic disorders."

The paper entitled "Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial" is available in an advanced online publication of Lancet on Thursday, August 21st (http://www.lancet.com).

About Cystic Fibrosis

Cystic fibrosis (CF) is a life-threatening genetic disease that causes serious lung infections and digestive complications. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. There is a commercially available genetic test to determine if a patient's CF is caused by a nonsense mutation, and it is estimated that nonsense mutations are the cause of CF in approximately 10 percent of patients in the United States and Europe and over 50 percent of patients in Israel. There is currently no available therapy to correct defective CFTR production and function. Instead, available treatments for CF are designed to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections, and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to a
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PTC124 Featured at Third Annual Congress of Myology
2. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
3. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
4. Atrium shows a strong financial performance for its first quarter
5. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
6. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
7. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
8. UW paper in Science shows how some solids mimic liquids on nanoscale
9. New research shows that iPods do not interfere with cardiac pacemakers
10. New kind of transistor radios shows capability of nanotube technology
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Traverse Biosciences announced today that it ... agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... for the treatment and control of periodontal disease ... Biosciences has also granted Aratana an exclusive option ... of periodontal disease in companion animals, inclusive of ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - The ... partners are pleased to announce the formation of ... on developing treatments for cancer that harness the ... represents a unique collaboration between the Children,s Hospital ... Research Institute, McMaster University, the Ontario Institute for ...
(Date:5/4/2015)... May 04, 2015 Genedata, a ... discovery and life science research, today announced the ... latest version of its enterprise solution for biologics ... enables more efficient discovery and development of novel ... integrate and address protein optimization and developability requirements. ...
(Date:5/4/2015)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... medical needs in the areas of inflammation, oncology and ... data from three of its biodefense programs at the ... on May 12-14, 2015 to be held at the ... St. Louis MO 63101. ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12
... 7 Endocare, Inc. (Nasdaq: ENDO ) ... have entered into a settlement agreement stipulating to termination ... Galil Medical pursuant to which Endocare would have acquired ... in Delaware Chancery Court. , , ...
... Covance Inc. today ... company as vice president and chief scientific officer of ... industry experience, including bioanalytical research, translational research, and talent ... development strategy for Covance,s bioanalytical services. , ...
... advanced energy research , , MONTREAL, July 7 ... technology company, today announced that it will jointly form ... Edmonton and the Alberta Energy Research Institute (AERI). , ... demonstration of novel catalytic conversion processes to produce advanced ...
Cached Biology Technology:Endocare and Galil Medical Announce Settlement of Litigation 2Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 3
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... Researchers at the Georgia Institute of Technology and the ... goal of automating the management of sedation in hospital intensive ... clinical data to accurately determine a patient,s level of sedation ... in the level. "ICU nurses have one of the ...
... more humanity acidifies and warms the world,s oceans with carbon ... our coral reefs. That,s the blunt message from a ... that ocean acidification and global warming will combine with local ... coral reefs right when they are struggling to survive. ...
... most common cardiac arrhythmia (abnormal heart rhythm). Its name ... muscles of the atria, instead of a coordinated contraction. ... in episodes lasting from minutes to weeks, or it ... alone is not in itself generally life-threatening, but it ...
Cached Biology News:Researchers working toward automating sedation in intensive care units 2Researchers working toward automating sedation in intensive care units 3Researchers working toward automating sedation in intensive care units 4Acid oceans demand greater reef care 2Moderate-to-heavy alcohol intake may increase risk of atrial fibrillation 2
...
...
... StdSens reagents and supplies, for 10 ... sufficient to perform standard-sensitivity RNA analysis ... the Experion automated electrophoresis system. Supplied ... microliters RNA StdSens stain, 20 microliters ...
... designed for enhanced translation of cloned sequences in ... lysate. The maps for pCITE-2b(+) and pCITE-2c(+) are ... pCITE-2b(+) is a 3793 bp plasmid; it lacks ... I sites. Subtract 7 bp from all sites ...
Biology Products: